DMRA
NASDAQDamora Therapeutics Inc.
News25/Ratings6
News · 26 weeks55+350%
2026-03-012026-08-23
Mix2890d
- SEC Filings12(43%)
- Other8(29%)
- Analyst4(14%)
- Insider3(11%)
- Leadership1(4%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Cheng Andrew4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- INSIDERSEC Form 3 filed by new insider Cheng Andrew3 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- SECSEC Form EFFECT filed by Damora Therapeutics Inc.EFFECT - Damora Therapeutics, Inc. (0001800315) (Filer)
- SECSEC Form S-8 POS filed by Damora Therapeutics Inc.S-8 POS - Damora Therapeutics, Inc. (0001800315) (Filer)
- SECSEC Form S-8 POS filed by Damora Therapeutics Inc.S-8 POS - Damora Therapeutics, Inc. (0001800315) (Filer)
- SECSEC Form POSASR filed by Damora Therapeutics Inc.POSASR - Damora Therapeutics, Inc. (0001800315) (Filer)
- SECSEC Form S-8 POS filed by Damora Therapeutics Inc.S-8 POS - Damora Therapeutics, Inc. (0001800315) (Filer)
- SECSEC Form S-8 POS filed by Damora Therapeutics Inc.S-8 POS - Damora Therapeutics, Inc. (0001800315) (Filer)
- SECSEC Form S-8 POS filed by Damora Therapeutics Inc.S-8 POS - Damora Therapeutics, Inc. (0001800315) (Filer)
- SECSEC Form S-8 POS filed by Damora Therapeutics Inc.S-8 POS - Damora Therapeutics, Inc. (0001800315) (Filer)
- SECSEC Form S-8 POS filed by Damora Therapeutics Inc.S-8 POS - Damora Therapeutics, Inc. (0001800315) (Filer)
- SECSEC Form S-8 POS filed by Damora Therapeutics Inc.S-8 POS - Damora Therapeutics, Inc. (0001800315) (Filer)
- SECSEC Form POS AM filed by Damora Therapeutics Inc.POS AM - Damora Therapeutics, Inc. (0001800315) (Filer)
- SECAmendment: SEC Form 8-A12B/A filed by Damora Therapeutics Inc.8-A12B/A - Damora Therapeutics, Inc. (0001800315) (Filer)
- PRDamora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights– Initiated the Phase 1/1b CLARITY-101 clinical trial of DMR-001 in patients with mutant calreticulin (mutCALR)-driven essential thrombocythemia (ET) and myelofibrosis (MF) – – Presented DMR-001 preclinical data at the European Hematology Association (EHA) 2026 Congress, showcasing best-in-class potential – – Appointed biotech veteran Dr. Andrew Cheng to the Board of Directors – – Strong financial position with $540.5 million in cash and cash equivalents as of June 30, 2026, expected to fund operations into the second half of 2029 – WALTHAM, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ:DMRA), a biotechnology company working to fundamentally redefin
- SECSEC Form 10-Q filed by Damora Therapeutics Inc.10-Q - Damora Therapeutics, Inc. (0001800315) (Filer)
- PRDamora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis-- DMR-001 is a highly potent, long-acting antibody therapy targeting Type 1 and non-Type 1 mutant calreticulin (mutCALR), designed for convenient once-monthly subcutaneous dosing -- -- In preclinical studies, DMR-001 demonstrated up to 30-fold greater potency and an approximately five-fold longer half-life than a reference anti-mutCALR antibody, supporting its best-in-class potential -- WALTHAM, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ:DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced the initiation of the global Phase 1/1b CLARITY-101 clinical trial of DMR-001, an investigational mo
- PRDamora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ:DMRA) ("Damora"), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to six newly-hired, non-executive employees on August 1, 2026. The inducement grants were approved by Damora’s independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals’ acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement grants consist of options to purchase an aggregate of 451,000 Damora ordinary shares with a 10-year term and an exercise pric
- ANALYSTJefferies initiated coverage on Damora Therapeutics with a new price targetJefferies initiated coverage of Damora Therapeutics with a rating of Buy and set a new price target of $50.00
- SECDamora Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Damora Therapeutics, Inc. (0001800315) (Filer)
- PRDamora Announces Redomestication from Delaware to Cayman IslandsBOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (Damora or the Company) (NASDAQ:DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced the completion of the redomestication of the Company from the State of Delaware to the Cayman Islands, effective on July 16, 2026. Each outstanding share of the Delaware Company’s common stock automatically converted into one ordinary share, par value $0.00001 per share, of the Company, and each outstanding share of any series of the Delaware Company’s preferred stock automatically converted into one outstanding share of the corresponding series of the preferred shares of
- INSIDERGeneral Counsel Winslow Garrett converted options into 680 shares and sold $7,345 worth of shares (245 units at $29.98), increasing direct ownership by 23% to 2,289 units (SEC Form 4) (for withholding tax)4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- PRDamora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ:DMRA) ("Damora"), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to nine newly-hired, non-executive employees on July 1, 2026. The inducement grants were approved by Damora’s independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals’ acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement grants consist of non-qualified stock options to purchase an aggregate of 453,500 shares of Damora’s common stock with a 10-ye
- SECDamora Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Damora Therapeutics, Inc. (0001800315) (Filer)
- ANALYSTH.C. Wainwright initiated coverage on Damora Therapeutics with a new price targetH.C. Wainwright initiated coverage of Damora Therapeutics with a rating of Buy and set a new price target of $45.00
DMRA FAQ
6 questionsWhere does DMRA stock trade?
Damora Therapeutics Inc. (DMRA) is listed on NASDAQ.What sector and industry is DMRA in?
Damora Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Damora Therapeutics Inc. go public?
Damora Therapeutics Inc. (DMRA) completed its IPO in 2020.What are analysts saying about DMRA?
Damora Therapeutics Inc. has had 6 recent analyst actions on file. The most recent action was from Jefferies: Buy on 2026-07-27. Recent price targets range from $3500.00 to $4600.00.What companies are similar to DMRA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare DMRA side-by-side with any of them on Quantisnow.How can I track DMRA on Quantisnow?
Quantisnow aggregates Damora Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DMRA to receive live email and push alerts on every new disclosure.